Multiple Myeloma Awareness Month: Advancing The Understanding of Targeted Therapies Role
March 14th 2023Multiple Myeloma expert Santhosh K Sadavish MD, discusses the importance of targeted therapies for these patients and how CAR T-cell therapy has changed the outcomes of patients who relapse after multiple lines of therapy.
New Solutions Continue to Show Up in the Lymphoma Treatment Landscape
March 9th 2023In an interview with Targeted Oncology, Matthew Matasar, MD, breaks down what he sees as some of the most exciting data in the field of treatment for patients with lymphoma and what the future may hold for this patient population.
Discussing Current and Potential Expansions to the Lymphoma Treatment Landscape
March 2nd 2023In an interview with Targeted Oncology, Matthew Matasar, MD, breaks down what he sees as some of the most exciting data in the field of treatment for patients with lymphoma and what the future may hold for this patient population.
Discussing the Long-term Impacts of Darolutamide in Nonmetastatic CRPC
February 26th 2023Discussing his presentation from the 2023 ASCO Genitourinary Symposium, Neal Shore, MD, FACS, looks at the long-term results of the phase 3 ARAMIS study for patients with nonmetastatic castration-resistant prostate cancer on darolutamide.
Iomab-B Shows Significant Improvement in R/R AML Over Chemotherapy Prior to Allogeneic HCT
February 19th 2023In findings from the phase 3 SIERRA trial, Iomab-B-based conditioning for patients with relapsed or refractory acute myeloid leukemia provided significant efficacy and tolerable safety results over the current standard of care.
Real-World Data Shows Survival Improvement for aGVHD After Ruxolitinib Introduction
February 17th 2023Looking at a retrospective analysis of data from a single-center, the use of ruxolitinib decreased non-relapse mortality and improved overall survival for patients with steroid-refractory acute graft-vs-host-disease.
Comparison of BTK Inhibitors Shows Promising Results for Zanubrutinib Over Ibrutinib in CLL/SLL
February 14th 2023An interim analysis of the phase 3 ALPINE study showed stronger results for patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma on the next generation BTK inhibitor zanubrutinib than standard of care ibrutinib.
Real-World Data Shows Wider Reach for Ide-Cel in RRMM
February 5th 2023After the results of the phase 2 KarMMa trial showed that idecabtagene vicleucel is a new standard of care in relapsed/refractory multiple myeloma, a real-world analysis continues to show the CAR T-cell therapy could have a wider reach.
Early Trial Results Show Promise for Combination of Lenvatinib, TACE, and Microwave Ablation in HCC
January 20th 2023Results from the phase 2 Talem trial, presented at the 2023 Gastrointestinal Cancers Symposium, showed the promising signs of efficacy, anti-tumor activity, and tolerable adverse events when combining blank-microsphere transarterial chemoembolization with lenvatinib and sequential microwave ablation for patients with HCC.
FDA Approves FoundationOne Companion Diagnostic to Entrectinib in NSCLC
January 6th 2023The FDA has approved the liquid biopsy next-generation sequencing-based test FoundationOne Liquid CDx in companion with entrectinib for patients with non–small cell lung cancer with a ROS1 mutation in their tumor.
The Impact of Advancements on the Current and Future Multiple Myeloma Landscape
January 4th 2023In an interview with Targeted Oncology, Jeffrey R. Schriber, MD, discussed the impact of new advancements in the treatment of multiple myeloma, like the use of BiTE cells, on the current and future landscape for this patient population.
Single Agent Belantamab Mafodotin Shows Deep and Durable Responses in Final Analysis of RRMM Study
December 12th 2022In a final analysis of the DREAMM-2 study, results showed the rapid and durable responses of belantamab mafodotin continued in patients with relapsed/refractory multiple myeloma despite ocular toxicities.
Adagrasib Plus Pembrolizumab Shows Promising Efficacy in Certain Patients with Advanced NSCLC
December 8th 2022Preliminary findings from the KRYSTAL-1 and KRYSTAL-7 trials show the potential for adagrasib in combination with pembrolizumab for patients with non-small cell lung cancer who’s cancer harbors a KRASG12C mutation.
Interim Survival Analysis of Sitravatinib Allows for SAPPHIRE Study Continuation in NSCLC
December 6th 2022An interim overall survival analysis of the novel therapy sitravatinib combined with nivolumab has cleared the way for a continuation of the phase 3 SAPPHIRE study in patients with advanced non-squamous non–small cell lung cancer.
FDA Requests Belantamab Mafodotin for R/R Multiple Myeloma Be Pulled From US Market
November 22nd 2022After an update from the phase 3 DREAMM-3 study the use of belantamab monotherapy for previously treated patients with relapsed or refractory multiple myeloma was pulled from US market authorization by request of the FDA.